Abstract
Objective To explore the clinical efficacy of ALIMTA (pemetrexed disodium) plus cisplatin.Methods Patients with malignant mesothelioma were allocated to two treatment groups envelope:pemetrexed plus cisplatin (PEM-group) or cisplatin alone (DDP-group).Results A total of 64 patients were randomly assigned and evaluated.The number of patients in PEM- and DDP-group had a significant pathologic complete response were (56.25 ％ vs 21.88 ％,x2 =7.943,P ＜0.05).Progression-free survival was significantly higher in PEM-group (P ＜0.05),and 2-year survival rate was lower in DDP-group (P ＜0.05).Conclusion Pemetrexed elicit significant tumor response and delays disease progression compared with DDP alone in patients with advanced MPM.Improvement in OS is seen in this study. Key words: Malignant pleural mesothelioma; Pemetrexed; Cisplatin; Drug therapy, combination; Progression-free survival; Survival rate
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
